Satellos Bioscience (MSLE) Cash & Equivalents (2023 - 2026)

Satellos Bioscience (MSLE) has reported Cash & Equivalents for 4 consecutive years, with $18.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents changed N/A year-over-year to $18.7 million; the TTM figure through Mar 2026 stood at $18.7 million (changed N/A YoY), while the FY2025 annual figure was $9.8 million, down 75.53% from the prior year.
• Cash & Equivalents advanced to $18.7 million in Q1 2026 per MSLE's latest filing, from $9.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $41.3 million in Q4 2024 and bottomed at $9.8 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $21.5 million across 4 years, with a median of $17.5 million in 2023.
• Annual changes were most pronounced in 2024 — Cash & Equivalents soared 154.64% — and 2025, when it plunged 76.25%.
• Satellos Bioscience's Cash & Equivalents stood at $16.2 million in 2023, then jumped by 154.64% to $41.3 million in 2024, then slumped by 76.25% to $9.8 million in 2025, then surged by 90.71% to $18.7 million in 2026.
• Business Quant data shows MSLE's Cash & Equivalents at $18.7 million in Q1 2026, $9.8 million in Q4 2025, and $41.3 million in Q4 2024.